Improving quality of care in inflammatory bowel disease: What changes can be made today?

被引:71
作者
Panes, Julian [1 ]
O'Connor, Marian [2 ]
Peyrin-Biroulet, Laurent [3 ,4 ]
Irving, Peter [5 ]
Petersson, Joel [6 ]
Colombel, Jean-Frederic [7 ]
机构
[1] Hosp Clin Barcelona, IDIBAPS, CIBERehd, E-08036 Barcelona, Spain
[2] St Marks Hosp, Harrow, Middx, England
[3] INSERM, U954, Nancy, France
[4] Univ Lorraine, Dept Gastroenterol, Nancy, France
[5] Guys & St Thomas Hosp, Dept Gastroenterol, London SE1 9RT, England
[6] AbbVie, Global Med Affairs Gastroenterol, Rungis, France
[7] Mt Sinai Sch Med, Dept Gastroenterol, New York, NY USA
关键词
Inflammatory bowel diseases; Crohn disease; Ulcerative colitis; IBD centres of excellence; Multidisciplinary team; Quality of care; CROHNS-DISEASE; ADHERENCE; INFLIXIMAB; THERAPY; PREFERENCES; PREVALENCE; MORTALITY; COLITIS; UTILITY; TRIAL;
D O I
10.1016/j.crohns.2014.02.022
中图分类号
R57 [消化系及腹部疾病];
学科分类号
100201 [内科学];
摘要
Background and aims: There are a number of gaps in our current quality of care for patients with inflammatory bowel diseases. This review proposes changes that could be made now to improve inflammatory bowel disease care. Methods: Evidence from the literature and clinical experience are presented that illustrate best practice for improving current quality of care of patients with inflammatory bowel diseases. Results: Best care for inflammatory bowel disease patients will involve services provided by a multidisciplinary team, ideally delivered at a centre of excellence and founded on current guidelines. Dedicated telephone support lines, virtual clinics and networking may also provide models through which to deliver high-quality, expert integrated patient care. Improved physician patient collaboration may improve treatment adherence, producing tangible improvements in disease outcomes, and may also allow patients to better understand the benefits and risks of a disease management plan. Coaching programmes and tools that improve patient self-management and empowerment are likely to be supported by payers if these can be shown to reduce long-term disability. Conclusions: Halting disease progression before there is widespread bowel damage and disability are ideal goals of inflammatory bowel disease management. Improving patient physician communication and supporting patients in their understanding of the evidence base are vital for ensuring patient commitment and involvement in the long-term management of their condition. Furthermore, there is a need to create more centres of excellence and to develop inflammatory bowel disease networks to ensure a consistent level of care across different settings. (C) 2014 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:919 / 926
页数:8
相关论文
共 42 条
[1]
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease [J].
Afif, Waqqas ;
Loftus, Edward V., Jr. ;
Faubion, William A. ;
Kane, Sunanda V. ;
Bruining, David H. ;
Hanson, Karen A. ;
Sandborn, William J. .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (05) :1133-1139
[2]
[Anonymous], 2013, Adherence to Long-Term Therapies: Evidence for Action, DOI DOI 10.4028/WWW.SCIENTIFIC.NET/AMM.321-324.1779
[3]
[Anonymous], 2013, Applications of motivational interviewing: Motivational interviewing: Helping people change
[4]
Patients' Preferences regarding Shared Decision-Making in the Treatment of Inflammatory Bowel Disease: Results from a Patient-Empowerment Study [J].
Baars, Judith E. ;
Markus, Tineke ;
Kuipers, Ernst J. ;
van der Woude, C. Janneke .
DIGESTION, 2010, 81 (02) :113-119
[5]
The immunogenic part of infliximab is the F(ab′)2, but measuring antibodies to the intact infliximab molecule is more clinically useful [J].
Ben-Horin, Shomron ;
Yavzori, Miri ;
Katz, Lior ;
Kopylov, Uri ;
Picard, Orit ;
Fudim, Ella ;
Coscas, Daniel ;
Bar-Meir, Simon ;
Goldstein, Itamar ;
Chowers, Yehuda .
GUT, 2011, 60 (01) :41-48
[6]
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies [J].
Bendtzen, Klaus ;
Ainsworth, Mark ;
Steenholdt, Casper ;
Thomsen, Ole Ostergaard ;
Brynskov, Jorn .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2009, 44 (07) :774-781
[7]
Adherence to thiopurine treatment in out-patients with Crohn's disease [J].
Bokemeyer, B. ;
Teml, A. ;
Roggel, C. ;
Hartmann, P. ;
Fischer, C. ;
Schaeffeler, E. ;
Schwab, M. .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2007, 26 (02) :217-225
[8]
Surgery for adult Crohn's disease: what is the actual risk? [J].
Bouguen, Guillaume ;
Peyrin-Biroulet, Laurent .
GUT, 2011, 60 (09) :1178-1181
[9]
Long-term evolution of disease behavior of Crohn's disease [J].
Cosnes, J ;
Cattan, S ;
Blain, A ;
Beaugerie, L ;
Carbonnel, F ;
Parc, R ;
Gendre, JP .
INFLAMMATORY BOWEL DISEASES, 2002, 8 (04) :244-250
[10]
New therapies for inflammatory bowel disease: from the bench to the bedside [J].
Danese, Silvio .
GUT, 2012, 61 (06) :918-932